Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | APOB | P04114 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795331 | 0.92 | SMO (0.43) | POLBOPRL1APOBMTTPSMO | |
| SCHEMBL6499727 | 0.88 | OPRL1 (0.43) | MAPTTP53POLBMGAT2OPRL1 | |
| SCHEMBL7201300 | 0.87 | TRPV4 (0.41) | OPRL1HTR2A | |
| SCHEMBL6492144 | 0.86 | LMNA (0.41) | MAPTTP53POLBNR3C1GCGR | |
| SCHEMBL6501001 | 0.83 | OPRL1 (0.43) | MAPTTP53POLBMGAT2OPRL1 | |
| SCHEMBL6500853 | 0.83 | CHRNB2 (0.42) | OPRL1GCGRAPOBMTTPSMO | |
| SCHEMBL6490835 | 0.81 | SMO (0.50) | NR3C1APOBMTTPSMOEGLN1 | |
| SCHEMBL6492604 | 0.80 | MTTP (0.42) | MAPTTP53POLBOPRL1GCGR | |
| SCHEMBL6499275 | 0.77 | MTTP (0.47) | MGAT2OPRL1APOBMTTPSMO | |
| SCHEMBL6491523 | 0.77 | KIT (0.42) | POLBGCGRAPOBMTTPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MAPT 4202/4885TP53 3031/4885POLB 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.